# Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

Source: https://onco.cc/trials/nct06581432/  
OnCo record `nct06581432` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Zongertinib in advanced solid tumours, run by Boehringer Ingelheim, now recruiting.

## Summary

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations is a phase 2 interventional study registered as NCT06581432 by Boehringer Ingelheim, with 588 participants planned, started 2024-10-11 and due to reach its primary completion in 2028-11-30. Interventions recorded: Zongertinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06581432
- Phase: 2
- Setting: Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours
- Sponsor: Boehringer Ingelheim
- Enrolled: 588

## Sources

- ClinicalTrials.gov NCT06581432: https://clinicaltrials.gov/study/NCT06581432

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Zongertinib](https://onco.cc/drugs/zongertinib/)
- companies: [Boehringer Ingelheim](https://onco.cc/companies/boehringer-ingelheim/)

---
JSON: https://onco.cc/api/v1/entities/nct06581432.json